Naming Glaxo's Strategy
Executive Summary
The acquisition of Wellcome is not Glaxo’s final move as its strategy continues to evolve. Having spent plenty of time negotiating non-research-based deals, like its never-completed three-way PBM deal with J&J and McKesson, it is likely continuing to explore channel management strategies, as are other drug companies (especially buying category or disease carveouts).